Over 5,000 genetic variants that enable certain cancers to thrive have been identified by scientists, along with a potential therapeutic target to treat or even prevent these cancers from developing.
FDA approves MSD’s KEYTRUDA regimen for MPM treatment
The combination of MSD’s KEYTRUDA and chemotherapy led to a statistically significant improvement in overall survival. Credit: ArDanMe/Shutterstock. The US Food and Drug Administration (FDA)